- Home
- ZNTL vs PRE Comparison
ZNTL vs PRE Comparison
Compare ZNTL & PRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZNTL | PRE |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.3M | 131.3M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZNTL | PRE |
|---|---|---|
| Price | $1.41 | $13.77 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 1 |
| Target Price | $5.87 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 554.4K | 138.2K |
| Earning Date | 11-10-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $26,865,000.00 | ★ $77,079,000.00 |
| Revenue This Year | N/A | $202.46 |
| Revenue Next Year | N/A | $103.60 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 201.54 |
| 52 Week Low | $1.01 | $3.10 |
| 52 Week High | $4.00 | $17.99 |
Technical Indicators
Market Signals| Indicator | ZNTL | PRE |
|---|---|---|
| Relative Strength Index (RSI) | 49.07 | 51.54 |
| Support Level | $1.31 | $13.45 |
| Resistance Level | $1.39 | $14.97 |
| Average True Range (ATR) | 0.07 | 1.22 |
| MACD | 0.01 | 0.12 |
| Stochastic Oscillator | 66.67 | 64.85 |
Price Performance
Historical ComparisonAbout ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About PRE Prenetics Global Limited
Prenetics Global Ltd is a health sciences company dedicated to consumer and clinical health. Its consumer initiative is led by IM8, a new health and wellness brand, and Europa, a U.S. sports distribution company. The clinical division is led by Insighta, focused on multi-cancer early detection technologies. This is followed by ACT Genomics, which has achieved FDA clearance for genomic profiling of solid tumors, and CircleDNA, which uses NGS to offer DNA tests. Each Prenetics unit impacts health by 'enhancing life through science'.